정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 996 | Not yet recruiting | New Treatment for COVID-19 Using Ethanol Vapor Inhalation . | Drug Effect | Drug: Ethanol with Asprin | Phase 3 | Mansoura University | OTHER | 80 | All | 20 Years ~ 60 Years | |
| 995 | Completed | Niclosamide for Mild to Moderate COVID-19 | COVID-19 | Drug: Niclosamide Drug: Placebo Other: Telehealth monitoring |
Phase 2 | Tufts Medical Center | OTHER | 73 | All | 18 Years | Tufts Medical Center, Boston, Massachusetts, United States |
| 994 | Not yet recruiting | Niclosamide in COVID-19 | Covid19 | Drug: Niclosamide Oral Tablet Drug: Placebo |
Phase 2 | First Wave Bio, Inc. | INDUSTRY | 148 | All | 18 Years | |
| 993 | Not yet recruiting | Niclosamide In Moderate COVID-19 | COVID | Drug: Niclosamide Oral Tablet Drug: Placebo |
Phase 2 | First Wave Bio, Inc. | INDUSTRY | 100 | All | 18 Years | |
| 992 | Recruiting | Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection | Acute Kidney Injury | Drug: Placebo Drug: Nicotinamide riboside |
Phase 2 | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | OTHER | 100 | All | 18 Years | Icahn School of Medicine at Mount Sinai, New York, New York, United States The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States University Health Systems, San Antonio, Texas, United States Harborview Medical Center, Seattle, Washington, United States |
| 991 | Completed | Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19 | Lymphopenia | Drug: nicotinamide | Not Applicable | Qiang Hu | OTHER | 24 | All | 18 Years ~ 85 Years | General Hospital of Northern Theater Command, Shenyang, Liaoning, China |
| 990 | Recruiting | Nigella 5 in the Treatment of SARS COV2 (COVID-19) | SARS-CoV2 Infection | Drug: Nigella Drug: Placebo |
Phase 1 | Hopital Universitaire Sahloul | OTHER | 500 | All | 40 Years | HU Sahloul, sousse, Tunisia, Sousse, Itineraire Ceinture Cite Sahloul, Tunisia Riadh Boukef, Sahloul, Sousse, Tunisia |